In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
By Moriah E Katt, Amanda L. Placone, Andrew D. Wong, Zinnia S. Xu, Peter C. Searson. Frontiers in Bioengineering and Biotechnology, 2016
683 citations recorded by the source corpus.
In vitro tumor models have provided important tools for cancer research and serve as low-cost screening platforms for drug therapies; however, cancer recurrence remains largely unchecked due to metastasis, which is the cause of the majority of cancer-related deaths. The need for an improved understanding of the progression and treatment of cancer has pushed for increased accuracy and physiological relevance of in vitro tumor models. As a result, in vitro tumor models have concurrently increased in complexity and their output parameters further diversified, since these models have progressed beyond simple proliferation, invasion, and cytotoxicity screens and have begun recapitulating critical steps in the metastatic cascade, such as intravasation, extravasation, angiogenesis, matrix remodeling, and tumor cell dormancy. Advances in tumor cell biology, 3D cell culture, tissue engineering, biomaterials, microfabrication, and microfluidics have enabled rapid development of new in vitro tumor models that often incorporate multiple cell types, extracellular matrix materials, and spatial and temporal introduction of soluble factors. Other innovations include the incorporation of perfusable microvessels to simulate the tumor vasculature and model intravasation and extravasation. The drive toward precision medicine has increased interest in adapting in vitro tumor models for patient-specific therapies, clinical management, and assessment of metastatic potential. Here, we review the wide range of current in vitro tumor models and summarize their advantages, disadvantages, and suitability in modeling specific aspects of the metastatic cascade and drug treatment.
Subfields: Biomedical Engineering, Biotechnology, Oncology
View Paper: https://www.semanticscholar.org/paper/a21c72350e553ba4d2a7a9d81216a561fad88583
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Oncology
Citations in the corpus
- Systems Biology of Cancer Metastasis (2019, background): “…that can be perturbed with relative ease, while also being able to incorporate some of the complexity of tumor microenvironments such as variations in mechanical properties, matrix chemistry, paracrine signals, and cell-cell interactions(Katt et al., 2016; Singh et al., 2018; Zanoni et al., 2016).”